SillaJen (215600) is declining during trading on the 8th. The share price is at 2,350 won, down 30 won from the previous trading day, a drop of 1.26%.

SillaJen announced on the 30th of last month that it had completed domestic patent registration for a technology that enables repeated intravenous dosing of an oncolytic virus.

◆ Core of the patent: 'neutralizing antibody escape' function The core of this patent registration is the neutralizing antibody escape function of the next-generation oncolytic virus platform 'SJ-607.' Neutralizing antibodies are antibodies that can block the action of a virus. When an oncolytic virus is administered repeatedly, this immune response can become an obstacle to the therapeutic virus performing its function. SJ-607 is a platform under development to enable repeated intravenous dosing through its neutralizing antibody escape function. This patent registration signifies securing domestic intellectual property rights for the technology.

◆ Patent registration must be distinguished from clinical success However, patent registration and proof of actual efficacy and safety as a therapeutic agent should be distinguished. Clinical outcomes or commercialization cannot be judged from this patent registration alone. Even after the patent registration news was announced, the stock price remained weak during trading that day.

[This article was written with AI assistance for informational purposes, based on publicly disclosed corporate announcements and intraday market prices. It does not recommend buying or selling any specific stock, and intraday prices are subject to change. Technological development and patent registration do not guarantee clinical success or commercialization, and responsibility for investment decisions and their outcomes lies with the investor.]